Revance Therapeutics Inc (RVNC)

$3.79

+0.03

(+0.8%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Revance Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 56.77M → 69.79M (in $), with an average increase of 18.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -141.17M → -55.69M (in $), with an average increase of 153.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 134.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 331.3%

Performance

  • $3.64
    $3.81
    $3.79
    downward going graph

    3.96%

    Downside

    Day's Volatility :4.46%

    Upside

    0.53%

    downward going graph
  • $3.72
    $37.98
    $3.79
    downward going graph

    1.85%

    Downside

    52 Weeks Volatility :90.21%

    Upside

    90.02%

    downward going graph

Returns

PeriodRevance Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-35.17%
-0.7%
0.0%
6 Months
-57.18%
6.6%
0.0%
1 Year
-87.69%
3.7%
-1.5%
3 Years
-86.2%
14.0%
-21.8%

Highlights

Market Capitalization
397.1M
Book Value
- $1.72
Earnings Per Share (EPS)
-3.83
PEG Ratio
-0.64
Wall Street Target Price
14.91
Profit Margin
-138.43%
Operating Margin TTM
-73.19%
Return On Assets TTM
-26.02%
Return On Equity TTM
-2096.78%
Revenue TTM
234.0M
Revenue Per Share TTM
2.77
Quarterly Revenue Growth YOY
39.800000000000004%
Gross Profit TTM
-20.4M
EBITDA
-207.0M
Diluted Eps TTM
-3.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.3
EPS Estimate Next Year
-1.06
EPS Estimate Current Quarter
-0.72
EPS Estimate Next Quarter
-0.62

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Revance Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
3
3
2
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 293.4%

Current $3.79
Target $14.91

Company Financials

FY18Y/Y Change
Revenue
3.7M
↑ 1323.28%
Net Income
-142.6M
↑ 18.23%
Net Profit Margin
-3.8K%
↑ 42202.35%
FY19Y/Y Change
Revenue
413.0K
↓ 88.92%
Net Income
-156.2M
↑ 9.57%
Net Profit Margin
-37.8K%
↓ 34001.72%
FY20Y/Y Change
Revenue
15.3M
↑ 3610.65%
Net Income
-282.1M
↑ 80.58%
Net Profit Margin
-1.8K%
↑ 35984.23%
FY21Y/Y Change
Revenue
77.8M
↑ 407.65%
Net Income
-286.8M
↑ 1.68%
Net Profit Margin
-368.68%
↑ 1472.03%
FY22Y/Y Change
Revenue
132.6M
↑ 70.4%
Net Income
-356.4M
↑ 24.27%
Net Profit Margin
-268.87%
↑ 99.81%
FY23Y/Y Change
Revenue
234.0M
↑ 76.55%
Net Income
-324.0M
↓ 9.1%
Net Profit Margin
-138.43%
↑ 130.44%
Q3 FY22Q/Q Change
Revenue
29.0M
↑ 2.28%
Net Income
-84.7M
↑ 37.72%
Net Profit Margin
-291.89%
↓ 75.11%
Q4 FY22Q/Q Change
Revenue
49.9M
↑ 72.05%
Net Income
-144.6M
↑ 70.68%
Net Profit Margin
-289.56%
↑ 2.33%
Q1 FY23Q/Q Change
Revenue
49.3M
↓ 1.18%
Net Income
-66.1M
↓ 54.31%
Net Profit Margin
-133.89%
↑ 155.67%
Q2 FY23Q/Q Change
Revenue
58.1M
↑ 17.84%
Net Income
-67.3M
↑ 1.92%
Net Profit Margin
-115.8%
↑ 18.09%
Q3 FY23Q/Q Change
Revenue
56.8M
↓ 2.34%
Net Income
-141.2M
↑ 109.72%
Net Profit Margin
-248.65%
↓ 132.85%
Q4 FY23Q/Q Change
Revenue
69.8M
↑ 22.94%
Net Income
-55.7M
↓ 60.55%
Net Profit Margin
-79.8%
↑ 168.85%
FY18Y/Y Change
Total Assets
226.3M
↓ 23.45%
Total Liabilities
80.7M
↑ 200.61%
FY19Y/Y Change
Total Assets
340.3M
↑ 50.34%
Total Liabilities
114.8M
↑ 42.21%
FY20Y/Y Change
Total Assets
720.2M
↑ 111.65%
Total Liabilities
345.9M
↑ 201.34%
FY21Y/Y Change
Total Assets
531.2M
↓ 26.25%
Total Liabilities
462.7M
↑ 33.75%
FY22Y/Y Change
Total Assets
581.9M
↑ 9.55%
Total Liabilities
569.3M
↑ 23.04%
FY23Y/Y Change
Total Assets
478.5M
↓ 17.78%
Total Liabilities
630.1M
↑ 10.67%
Q3 FY22Q/Q Change
Total Assets
711.6M
↑ 26.64%
Total Liabilities
565.9M
↑ 0.24%
Q4 FY22Q/Q Change
Total Assets
581.9M
↓ 18.23%
Total Liabilities
569.3M
↑ 0.6%
Q1 FY23Q/Q Change
Total Assets
547.8M
↓ 5.86%
Total Liabilities
574.5M
↑ 0.91%
Q2 FY23Q/Q Change
Total Assets
597.5M
↑ 9.08%
Total Liabilities
570.7M
↓ 0.65%
Q3 FY23Q/Q Change
Total Assets
532.5M
↓ 10.89%
Total Liabilities
638.7M
↑ 11.9%
Q4 FY23Q/Q Change
Total Assets
478.5M
↓ 10.15%
Total Liabilities
630.1M
↓ 1.35%
FY18Y/Y Change
Operating Cash Flow
-104.2M
↑ 9.34%
Investing Cash Flow
-107.0M
↓ 190.1%
Financing Cash Flow
1.8M
↓ 99.09%
FY19Y/Y Change
Operating Cash Flow
-106.2M
↑ 1.84%
Investing Cash Flow
-17.6M
↓ 83.56%
Financing Cash Flow
221.7M
↑ 12338.66%
FY20Y/Y Change
Operating Cash Flow
-178.5M
↑ 68.14%
Investing Cash Flow
12.1M
↓ 168.96%
Financing Cash Flow
331.5M
↑ 49.55%
FY21Y/Y Change
Operating Cash Flow
-221.5M
↑ 24.11%
Investing Cash Flow
-29.7M
↓ 344.54%
Financing Cash Flow
29.9M
↓ 90.99%
FY22Y/Y Change
Operating Cash Flow
-193.5M
↓ 12.63%
Investing Cash Flow
-138.8M
↑ 367.88%
Financing Cash Flow
331.7M
↑ 1010.5%
Q3 FY22Q/Q Change
Operating Cash Flow
-57.9M
↑ 30.86%
Investing Cash Flow
-118.4M
↑ 11.87%
Financing Cash Flow
211.4M
↑ 898.77%
Q4 FY22Q/Q Change
Operating Cash Flow
-30.2M
↓ 47.85%
Investing Cash Flow
41.0M
↓ 134.58%
Financing Cash Flow
-6.2M
↓ 102.92%
Q1 FY23Q/Q Change
Operating Cash Flow
-69.5M
↑ 130.27%
Investing Cash Flow
95.3M
↑ 132.71%
Financing Cash Flow
3.3M
↓ 152.89%
Q2 FY23Q/Q Change
Operating Cash Flow
-53.4M
↓ 23.19%
Investing Cash Flow
-39.5M
↓ 141.47%
Financing Cash Flow
97.5M
↑ 2885.33%

Technicals Summary

Sell

Neutral

Buy

Revance Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Revance Therapeutics Inc
Revance Therapeutics Inc
-23.89%
-57.18%
-87.69%
-86.2%
-72.13%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Revance Therapeutics Inc
Revance Therapeutics Inc
NA
NA
-0.64
-2.3
-20.97
-0.26
NA
-1.72
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Revance Therapeutics Inc
Revance Therapeutics Inc
Buy
$397.1M
-72.13%
NA
-138.43%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Capital World Investors

    11.46%

  • BlackRock Inc

    7.15%

  • Palo Alto Investors, LLC

    5.03%

  • Vanguard Group Inc

    4.86%

  • Franklin Resources Inc

    4.56%

  • JPMorgan Chase & Co

    4.46%

Corporate Announcements

  • Revance Therapeutics Inc Earnings

    Revance Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form

Organization
Revance Therapeutics Inc
Employees
597
CEO
Mr. Mark J. Foley
Industry
Health Technology

Discover More

FAQs